Zidovudine: A salvage therapy for mcr-1 plasmid-mediated colistin-resistant bacterial infections?

International Journal of Antimicrobial Agents

Volumn 52, Issue 1, 2018, Pages 11-13

  Peyclit, Lucie ^a   Baron, Sophie A ^a   Yousfi, Hanane ^a   Rolain, Jean Marc ^a  

^a Institut Hospitalo Universitaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; COLISTIN; FOSFOMYCIN; MINOCYCLINE; THYMIDINE KINASE; TIGECYCLINE; ZIDOVUDINE; ANTIINFECTIVE AGENT; ESCHERICHIA COLI PROTEIN; MCR-1 PROTEIN, E COLI;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD TOXICITY; CEREBROSPINAL FLUID; CLINICAL EFFECTIVENESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG REPOSITIONING; DRUG SCREENING; EDITORIAL; ENTEROBACTERIACEAE; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; LONG TERM CARE; MAXIMUM CONCENTRATION; MCR 1 PLASMID; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOKINETIC PARAMETERS; PLASMID; PREGNANCY OUTCOME; PRIORITY JOURNAL; SALVAGE THERAPY; SEPSIS; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; VOLUNTEER; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PLASMIDS; SALVAGE THERAPY; ZIDOVUDINE;

EID: 85047068271     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.03.012     Document Type: Editorial

References (29)

1. Tacconelli, E, Carrara, E, Savoldi, A, Harbarth, S, Mendelson, M, Monnet, DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18 (2018), 318–327.
2. Liu, YY, Wang, Y, Walsh, TR, Yi, LX, Zhang, R, Spencer, J, et al. Emergence of plasmid-mediated colistin resistance mechanism mcr-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16 (2016), 161–168.
3. Baron, S, Hadjadj, L, Rolain, JM, Olaitan, AO, Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents 48 (2016), 583–591.
4. Rolain, JM, Abat, C, Jimeno, MT, Fournier, PE, Raoult, D, Do we need new antibiotics?. Clin Microbiol Infect 22 (2016), 408–415.
5. Dubourg, G, Okdah, L, Le Page, S, Rolain, JM, Raoult, D, In vitro activity of 'old antibiotics' against highly resistant Gram-negative bacteria. Int J Antimicrob Agents 46 (2015), 718–720.
6. Cassir, N, Rolain, JM, Brouqui, P, A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol, 5, 2014, 551.
7. Pulcini, C, Mohrs, S, Beovic, B, Gyssens, I, Theuretzbacher, U, Cars, O, et al. Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents 49 (2017), 98–101.
8. Ng, SMS, Sioson, JSP, Yap, JM, Ng, FM, Ching, HSV, Teo, JWP, et al. Repurposing zidovudine in combination with tigecycline for treating carbapenem-resistant Enterobacteriaceae infections. Eur J Clin Microbiol Infect Dis 37 (2018), 141–148.
9. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 2009; 10:61–71.
10. Elwell, LP, Ferone, R, Freeman, GA, Fyfe, JA, Hill, JA, Ray, PH, et al. Antibacterial activity and mechanism of action of 3′-azido-3′-deoxythymidine (BW A509U). Antimicrob Agents Chemother 31 (1987), 274–280.
11. Keith, BR, White, G, Wilson, HR, In vivo efficacy of zidovudine (3′-azido-3′-deoxythymidine) in experimental Gram-negative-bacterial infections. Antimicrob Agents Chemother 33 (1989), 479–483.
12. Doléans-Jordheim, A, Bergeron, E, Bereyziat, F, Ben-Larbi, S, Dumitrescu, O, Mazoyer, MA, et al. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. Eur J Clin Microbiol Infect Dis 30 (2011), 1249–1256.
13. Lewin, CS, Allen, RA, Amyes, SG, Mechanisms of zidovudine resistance in bacteria. J Med Microbiol 33 (1990), 235–238.
14. Taburet, AM, Naveau, S, Zorza, G, Colin, JN, Delfraissy, JF, Chaput, JC, et al. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Ther 47 (1990), 731–739.
15. Wattanagoon, Y, Na Bangchang, K, Hoggard, PG, Khoo, SH, Gibbons, SE, Phiboonbhanakit, D, et al. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers. Antimicrob Agents Chemother 44 (2000), 1986–1989.
16. Pickus, OB, Overdose of zidovudine. N Engl J Med, 318, 1988, 1206.
17. Balis, FM, Pizzo, PA, Murphy, RF, Eddy, J, Jarosinski, PF, Falloon, J, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 110 (1989), 279–285.
18. Sperling, R.Zidovudine, Infect Dis Obstet Gynecol 6 (1998), 197–203.
19. Lewin, CS, Watt, B, Paton, R, Amyes, SG, Isolation of zidovudine resistant Escherichia coli from AIDS patients. FEMS Microbiol Lett 58 (1990), 141–143.
20. Lewin, CS, Allen, R, Amyes, SG, Zidovudine-resistance in Salmonella typhimurium and Escherichia coli. J Antimicrob Chemother 25 (1990), 706–708.
21. Casado, JL, Valdezate, S, Calderon, C, Navas, E, Frutos, B, Guerrero, A, et al. Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients. J Infect Dis 179 (1999), 1553–1556.
22. Olaitan, AO, Chabou, S, Okdah, L, Morand, S, Rolain, JM, Dissemination of the mcr-1 colistin resistance gene. Lancet Infect Dis, 16, 2016, 147.
23. Leangapichart, T, Gautret, P, Brouqui, P, Mimish, Z, Raoult, D, Rolain, JM, Acquisition of mcr-1 plasmid-mediated colistin resistance in Escherichia coli and Klebsiella pneumoniae during Hajj 2013 and 2014. Antimicrob Agents Chemother 60 (2016), 6998–6999.
24. Berrazeg, M, Hadjadj, L, Ayad, A, Drissi, M, Rolain, JM, First detected human case in Algeria of mcr-1 plasmid-mediated colistin resistance in a 2011 Escherichia coli isolate. Antimicrob Agents Chemother 60 (2016), 6996–6997.
25. Al Bayssari, C, Olaitan, AO, Dabboussi, F, Hamze, M, Rolain, JM, Emergence of OXA-48-producing Escherichia coli clone ST38 in fowl. Antimicrob Agents Chemother 59 (2015), 745–746.
26. Sassi, A, Loucif, L, Gupta, SK, Dekhil, M, Chettibi, H, Rolain, JM, NDM-5 carbapenemase-encoding gene in multidrug-resistant clinical isolates of Escherichia coli from Algeria. Antimicrob Agents Chemother 58 (2014), 5606–5608.
27. Olaitan, AO, Diene, SM, Kempf, M, Berrazeg, M, Bakour, S, Gupta, SK, et al. Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study. Int J Antimicrob Agents 44 (2014), 500–507.
28. Bakour, S, Sahli, F, Touati, A, Rolain, JM, Emergence of KPC-producing Klebsiella pneumoniae ST512 isolated from cerebrospinal fluid of a child in Algeria. New Microbes New Infect 3 (2014), 34–36.
29. Rolain, JM, François, P, Hernandez, D, Bittar, F, Richet, H, Fournous, G, et al. Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage. Biol Direct, 4, 2009, 1.